Teva Pharmaceutical Industries to Participate in Major Conferences
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) recently announced an exciting opportunity for stakeholders and health enthusiasts alike. With a commitment to advancing healthcare, Richard Francis, Teva's President and CEO, will represent the company at two noteworthy investor conferences this November.
Details on the Conferences
The upcoming engagement includes:
- UBS Global Healthcare Conference, scheduled for Monday, November 10, 2025, at 8:45 A.M. Eastern Time (ET).
- Jefferies London Healthcare Conference, set for Tuesday, November 18, 2025, at 11:00 A.M. Greenwich Mean Time (6:00 A.M. ET).
These platforms will provide Teva an opportunity to showcase their ongoing initiatives and developments in the biopharmaceutical landscape.
Webcast Access and Availability
For those interested in joining the discussions remotely, a live webcast will be accessible through Teva's Investor Relations website. This initiative ensures that a wider audience can be a part of the conversations surrounding the future of healthcare and innovation.
An archived version of the webcast will also be available within 24 hours after the conclusion of each presentation, allowing those who cannot attend live to catch up on the insights shared.
Teva's Commitment to Better Health
With a history that spans more than a century, Teva continues to be a frontrunner in the pharmaceutical industry. The company is not just recognized for its robust generics business but also as a pioneer in innovative biopharmaceutical products.
In recent years, Teva has dedicated its resources to enhancing fields such as neuroscience and immunology. Their mission extends beyond producing medications; it involves a commitment to address the evolving needs of patients worldwide, underscoring the message that at Teva, "We Are All In For Better Health." The burgeoning pipeline of innovative treatments and biosimilars demonstrates Teva's proactive approach to meeting health challenges today and in the future.
Future Prospects and Strategies
As Teva progresses, the company is prioritizing its "Pivot to Growth" strategy, focusing on expanding its portfolio of innovative and biosimilar medicines. This strategic move aims to enhance their competitive standing and support sustainable growth in a complex market.
In light of significant changes and challenges in the industry, Teva is navigating a landscape filled with both risks and opportunities. Their ability to adapt and innovate will be critical as they execute an organizational transformation that aims not only to unveil new products but also to realize expected cost efficiencies.
Staying Engaged with Stakeholders
Teva understands the importance of maintaining transparent communication with its stakeholders. The media and investor relations teams are dedicated to providing up-to-date information regarding the company's endeavors.
For inquiries, Teva's communications team can be reached at TevaCommunicationsNorthAmerica@tevapharm.com. Investors can connect with them through TevaIR@Tevapharm.com for any investment-related questions. This openness reflects Teva's dedication to keeping its community informed and engaged.
Frequently Asked Questions
What is the main focus of Teva's presentation at the conferences?
The main focus will be on showcasing Teva's innovative initiatives and future directions in the biopharmaceutical industry.
When are the dates of the upcoming healthcare conferences?
The UBS Global Healthcare Conference is on November 10, 2025, and the Jefferies London Healthcare Conference is on November 18, 2025.
How can I access the live webcast of the presentations?
You can access the live webcast through Teva's Investor Relations website during the scheduled presentation times.
What future strategies is Teva implementing?
Teva is implementing its "Pivot to Growth" strategy, focusing on expanding its innovative and biosimilar medicines portfolio to promote sustainable growth.
How can stakeholders contact Teva for inquiries?
Stakeholders can contact Teva’s media inquiries at TevaCommunicationsNorthAmerica@tevapharm.com and for investor relations, they can use TevaIR@Tevapharm.com.
